Filter
Reset all

Subjects

Content Types

Countries

AID systems

API

Certificates

Data access

Data access restrictions

Database access

Database licenses

Data licenses

Data upload

Enhanced publication

Institution responsibility type

Institution type

Keywords

PID systems

Provider types

Quality management

Repository languages

Software

Syndications

Repository types

Versioning

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
  • 1 (current)
Found 8 result(s)

GePaRD

German Pharmacoepidemiological Research Database

Subject(s)
Content type(s)
Country
Since 2004, the Leibniz Institute for Prevention Research and Epidemiology – BIPS has been working on the establishment and maintenance of the project-based German Pharmacoepidemiological Research Database (short GePaRD). GePaRD is based on claims data from statutory health insurance (SHI) providers and currently includes information on about 20 million persons who have been insured with one of the participating providers since 2004. Per data year, there is information on approximately 17% of the general population from all geographical regions of Germany.

Health Canada Drug Product Database

DPD

Subject(s)
Content type(s)
Country
The Health Canada Drug Product Database contains product specific information on drugs approved for use in Canada. The database is managed by Health Canada and includes human pharmaceutical and biological drugs, veterinary drugs and disinfectant products. It contains approximately 15,000 products which companies have notified Health Canada as being marketed.

PharmGKB

Pharmacogenomics Knowledgebase

Subject(s)
Content type(s)
Country
PharmGKB is a comprehensive resource that curates knowledge about the impact of genetic variation on drug response for clinicians and researchers. PharmGKB brings together the relevant data in a single place and adds value by combining disparate data on the same relationship, making it easier to search and easier to view the key aspects and by interpreting the data.PharmGKB provide clinical interpretations of this data, curated pathways and VIP summaries which are not found elsewhere.

ConsensusPathDB

CPDB

Subject(s)
Content type(s)
Country
ConsensusPathDB integrates interaction networks in humans (and in the model organisms - yeast and mouse) including binary and complex protein-protein, genetic, metabolic, signaling, gene regulatory and drug-target interactions, as well as biochemical pathways. Data originate from public resources for interactions and interactions curated from the literature. The interaction data are integrated in a complementary manner to avoid redundancies.

SuperTarget

Subject(s)
Content type(s)
Country
<<<!!!<<< This repository is no longer available. >>>!!!>>>

Hazardous Substance Data Bank

HSDB

Subject(s)
Content type(s)
Country
<<<!!!<<< The repository is no longer available. >>>!!!>>>The information is accessible through PubChem:https://pubchem.ncbi.nlm.nih.gov/. Help for HSDB Users in PubChem PDF: https://www.nlm.nih.gov/toxnet/Accessing_HSDB_Content_from_PubChem.pdf Help for HSDB Users in PubChem Web Page: https://www.nlm.nih.gov/toxnet/Accessing_HSDB_Content_from_PubChem.html <<<!!!>>>

Liverpool COVID-19 Drug Interactions

Subject(s)
Content type(s)
Country
The COVID-19 pandemic has affected every country in the world. It is well documented that those most susceptible to the worst outcomes of COVID-19 are the immunocompromised and those with underlying comorbidities. Therefore, patients requiring treatment for COVID-19 will also be on additional medication, posing a risk for drug-drug interactions (DDIs). In order to address this, the Liverpool Drug Interactions website team developed this freely available drug interactions resource to provide information on the likelihood of interactions between the experimental agents used for the treatment of COVID-19 and commonly prescribed co-medications.

Screening Unit Berlin-Buch

Screening Unit Jens Peter von Kries

Subject(s)
Content type(s)
Country
The mission of the platform is to enable access for academic projects towards experiments in high-throughput without loss of IP and on a cost basis, which does not restrict access towards HTS usage. The FMP hosts the central open access technology platform of EU-OPENSCREEN, the ChemBioNet and theHelmholtz-Initiative für Wirkstoffforschung, the Screening Unit. The Unit serves for systematic screening of large compound or genome-wide RNAi libraries with state-of-the-art equipment like automated microscopes and microfluidic systems. The Screening Unit is part of the Chemical Biology Platform of the FMP also supported by the MDC. See also: https://www.mdc-berlin.de/screening-unit